Please select the option that best describes you:
When should we consider screening patients with systemic sarcoidosis for cardiac involvement
using cardiac MRI or PET given their high risk for sudden cardiac death and discrepancies between reported cardiac symptoms (2-5%) and evidence of cardiac inflammation on advanced imaging and autopsy findings (>25% of cases)?